Wire · operational-macro
Teva saddles up as stalking horse bidder for bankrupt BioXcel's neuroscience portfolio
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 August 2026 · Fusion42 review
Teva Pharmaceutical has emerged as the stalking horse bidder for the bankrupt BioXcel Therapeutics' neuroscience portfolio, with a deal valuing the assets at $57.5 million upfront and up to $67.5 million in milestones. BioXcel's asset BXCL501, an oral film drug under FDA review for agitation in bipolar disorder and schizophrenia, is central to the acquisition and could generate significant milestone payments if approved.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
Teva is moving quickly to take over assets from a bankrupt biotech, creating a buying opportunity and market consolidation in neuroscience drugs for agitation in mental health. If you are building biotech platforms or therapies in neuroscience, this deal reshuffles competitive pressures and potential partnerships in your space.
◆ Coverage
2 sources · 28 Aug 2026
◆ Related on Wire
◆ Topics